Stephen Maxted Ansell, MD, PhD

  • 22954 Citations
  • 81 Scopus h-Index
1989 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

Filter
Comment/debate
2019

Activation-induced T-cell exhaustion: too much of a good thing?

Ansell, S. M., Jan 1 2019, (Accepted/In press) In : Leukemia and Lymphoma.

Research output: Contribution to journalComment/debate

Pembrolizumab: Living up to expectations

Ansell, S. M., Oct 3 2019, In : Blood. 134, 14, p. 1114-1115 2 p.

Research output: Contribution to journalComment/debate

2 Scopus citations

Prognostic significance of PD-L1 and TLR5 expression in peripheral T-cell lymphomas

Zanwar, S. & Ansell, S. M., Jan 1 2019, In : Leukemia and Lymphoma.

Research output: Contribution to journalComment/debate

Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma

Ansell, S. M., Jan 1 2019, In : The Lancet Haematology. 6, 1, p. e2-e3

Research output: Contribution to journalComment/debate

2017

Anti-CD20-IL-21 fusokine: The tail wags the dog

Ansell, S. M., Apr 20 2017, In : Blood. 129, 16, p. 2209-2210 2 p.

Research output: Contribution to journalComment/debate

2015

DNA methylation in lymphoma: An opportunity?

Ansell, S. M., Mar 19 2015, In : Blood. 125, 12, p. 1848-1849 2 p.

Research output: Contribution to journalComment/debate

4 Scopus citations

The era of immuno-oncology: are we there yet?

Villasboas Bisneto, J. J. C. . & Ansell, S. M., Mar 1 2015, In : Oncology (Williston Park, N.Y.). 29, 3, p. 204-205 2 p.

Research output: Contribution to journalComment/debate

2014

Follicular lymphoma: Watch and wait is watch and worry

Ansell, S. M., Apr 2014, In : The Lancet Oncology. 15, 4, p. 368-369 2 p.

Research output: Contribution to journalComment/debate

3 Scopus citations
2008

Wnt-erizing mantle cell lymphoma

Ansell, S. M., Dec 15 2008, In : Blood. 112, 13, p. 4783-4784 2 p.

Research output: Contribution to journalComment/debate